Tuesday’s trading session was great for the price of Neurocrine Biosciences Inc. (NBIX) stock, which skyrocketed $8.75 (or +89.69%) to $18.51, after the company reported positive data from a study utilizing the capsule formulation of its NBI-98854, a small molecule VMAT2 inhibitor, in moderate to severe tardive dyskinesia patients. Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)…